m1069
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 2, 2022 (NCT05198349)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-2b adrenergic receptorANTAGONIST
ADRA2B antagonist
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05198349 | Phase 1 | Mar 2, 2022 | Merck KGaA, Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2022 |
| Merck Serono | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1